Tab Osimertinib 80mg, sold under the name LucioSim by Lucius Pharmaceuticals, is a targeted treatment designed for people with a specific type of non‑small cell lung cancer (NSCLC). It is especially effective for patients whose cancer has a mutation called T790M, whether or not they have been treated with an EGFR tyrosine kinase inhibitor (TKI) before.
In many cases of NSCLC, mutations in the EGFR gene cause cancer cells to grow and divide uncontrollably. While earlier treatments that target EGFR mutations can be helpful, some cancers develop resistance due to the T790M mutation.
LucioSim works by:
- Targeting the original EGFR mutation that causes cancer.
- Blocking the T790M resistance mutation, helping to stop the cancer from growing even after earlier treatments stop working.
This dual action makes LucioSim a valuable option for patients whose cancer has become resistant to other EGFR‑targeted therapies.
